A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE
WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR
OVERWEIGHT (SURPASS-T1D-2)
- Registry ID
- I8F-MC-GPJD
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2025-10-18
- Last update
- 2025-03-20
Conditions
- TYPE 1 DIABETES
- OVERWEIGHT/OBESITY
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY {VESPER 6)
- A PHASE II, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, 42-WEEK DOSE-FINDING TRIAL FOR BI 3034701 ADMINISTERED SUBCUTANEOUSLY COMPARED TO PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT
- A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF ELECOGLIPRON IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS (EMBOLD)
- A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-3)
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES
View on source registry